Amid a roller-coaster end to 2024 for the stock market, dividend-paying stocks continued to lag the broader market. However, ...

MitoRx Therapeutics strengthens its leadership with the appointments of Lubor Gaal as chief business officer and Stacey ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

International Assets Investment Management LLC cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 98.4% ...

Highlights,Bristol-Myers Squibb beats quarterly earnings estimates.,Dividend increased, maintaining strong returns.,Insider ...

Pfizer (PFE), GSK (GSK), and AbbVie (ABBV) are worth considering. ETFs that offer dividends and growth include that from Schwab (SCHD). Value stocks in the REIT are not as attractive, nor are ...

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...

Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...

(Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers ...

Highlights,Bristol-Myers Squibb manages its debt effectively with solid earnings.,A substantial cash reserve supports the ...